CGEM (STOCKS)
Cullinan Therapeutics, Inc. Common Stock
$15.400000
+0.960000 (+6.65%)
Prev close: $14.440000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Nadim Ahmed
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $931.58M
- Employees
- 111
- P/E (TTM)
- -4.05
- P/B (TTM)
- 2.44
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.75 | $-0.85 | +0.0953 | +11.27% |
|
Dec 2025 (Q4)
|
$-0.77 | $-0.83 | +0.0556 | +6.73% |
|
Sep 2025 (Q3)
|
$-0.77 | $-0.98 | +0.2064 | +21.14% |
|
Jun 2025 (Q2)
|
$-1.07 | $-0.85 | -0.2203 | -25.93% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $240.35M |
| Research and Development | $188.07M |
| Other Operating Expenses | $51.98M |
| Operating Income/Loss | -$240.35M |
| Income/Loss From Continuing Operations After Tax | -$221.04M |
| Income/Loss From Continuing Operations Before Tax | -$221.04M |
| Net Income/Loss | -$221.04M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$221.04M |
| Net Income/Loss Available To Common Stockholders, Basic | -$221.04M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $402.98M |
| Current Assets | $361.41M |
| Cash | $351.90M |
| Prepaid Expenses | $9.52M |
| Noncurrent Assets | $41.58M |
| Fixed Assets | $342.00K |
| Other Non-current Assets | $41.24M |
| Liabilities | $36.81M |
| Current Liabilities | $35.15M |
| Accounts Payable | $2.51M |
| Other Current Liabilities | $32.65M |
| Noncurrent Liabilities | $1.66M |
| Equity | $366.17M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $366.17M |
| Liabilities And Equity | $402.98M |
| Net Cash Flow From Operating Activities | -$178.64M |
| Net Cash Flow From Operating Activities, Continuing | -$178.64M |
| Net Cash Flow From Investing Activities | $175.60M |
| Net Cash Flow From Investing Activities, Continuing | $175.60M |
| Net Cash Flow From Financing Activities | -$4.88M |
| Net Cash Flow From Financing Activities, Continuing | -$4.88M |
| Net Cash Flow | -$7.92M |
| Net Cash Flow, Continuing | -$7.92M |
| Comprehensive Income/Loss | -$221.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$221.42M |
| Other Comprehensive Income/Loss | -$480.00K |